PharmaBoardroom

Niche generics manufacturer Rivopharm was nearly bankrupt when acquired by current president and CEO Piero Poli in 2005; he explains the changes and…

www.celonic.com CEO of Swiss biologics CDMO Celonic, Konstantin Matentzoglu, explains how the company attracts talented and experienced staff and…

As the largest privately owned pharmaceutical company in Switzerland, IBSA remains committed to continuing to invest and manufacture in Switzerland.…

Jesús Martin-Garcia, Chairman and CEO of GeNeuro, discusses their positive partnership with Servier to develop an antibody against a possible cause…

Managing volatility – the CEO of Acino, a Swiss pharmaceutical player, elaborates on the company’s unique strategy based on its significant…

The Services Delivery Director for Life Sciences of NNIT Switzerland talks big data and highlights how this trend needs to be approached in order to…

Daniel Schmutz, CEO of Switzerland’s leading insurance company, Helsana, sketches out the Swiss health insurance landscape, how his company…

LEO Pharma’s Country Lead for Switzerland, Patrick Brunner, discusses the skincare specialist’s most important products, the Swiss affiliate’s…

The President of FASMED—the Swiss medical technology industry and trade association—elaborates on the plans to join forces with Medical Cluster,…

Ensuring a fair allocation of rights and returns from collaboratively developed technologies is a continual challenge for university Tech Transfer…

Beat Berger (BB) and Dr Uwe Schmelzer (US) of Swiss API distributor DCS Pharma discuss growth segments in the global generics market, international…

Not all impactful innovation involves the development of new chemical or biological entities, and the value of such innovation must be recognized in…